Abstract
A patient with triosephosphate isomerase (TPI) deficiency exhibited worsening of abnormal involuntary movements of the dystonic type and developed psychiatric symptoms while on selegiline. When selegiline was stopped after 9 years of treatment, abnormal involuntary movements improved to pretreatment level and psychiatric behaviour returned to normal. Monoamine oxidase-B platelet activity was low in this patient.
Copyright 2003 Movement Disorder Society
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Anemia, Hemolytic, Congenital / enzymology
-
Anemia, Hemolytic, Congenital / genetics*
-
Antiparkinson Agents / adverse effects*
-
Antiparkinson Agents / therapeutic use
-
Baclofen / adverse effects
-
Baclofen / therapeutic use
-
Basal Ganglia / drug effects
-
Basal Ganglia Diseases / drug therapy
-
Basal Ganglia Diseases / enzymology
-
Basal Ganglia Diseases / genetics*
-
Blood Platelets / enzymology
-
Drug Therapy, Combination
-
Dyskinesia, Drug-Induced / diagnosis
-
Dyskinesia, Drug-Induced / etiology*
-
Dystonia Musculorum Deformans / drug therapy
-
Dystonia Musculorum Deformans / enzymology
-
Dystonia Musculorum Deformans / genetics*
-
Female
-
Genetic Carrier Screening
-
Genotype
-
Glyceraldehyde-3-Phosphate Dehydrogenases / deficiency*
-
Glyceraldehyde-3-Phosphate Dehydrogenases / genetics
-
Humans
-
Huntingtin Protein
-
Long-Term Care
-
Male
-
Middle Aged
-
Monoamine Oxidase / blood
-
Monoamine Oxidase / genetics
-
Monoamine Oxidase Inhibitors / adverse effects*
-
Monoamine Oxidase Inhibitors / therapeutic use
-
Nerve Tissue Proteins / genetics
-
Neurologic Examination / drug effects
-
Neuroprotective Agents / adverse effects*
-
Neuroprotective Agents / therapeutic use
-
Nuclear Proteins / genetics
-
Polymerase Chain Reaction
-
Proteins / genetics
-
Psychoses, Substance-Induced / diagnosis
-
Psychoses, Substance-Induced / etiology*
-
Reference Values
-
Selegiline / adverse effects*
-
Selegiline / therapeutic use
-
Trinucleotide Repeats
Substances
-
Antiparkinson Agents
-
HTT protein, human
-
Huntingtin Protein
-
Monoamine Oxidase Inhibitors
-
Nerve Tissue Proteins
-
Neuroprotective Agents
-
Nuclear Proteins
-
Proteins
-
Selegiline
-
Glyceraldehyde-3-Phosphate Dehydrogenases
-
Monoamine Oxidase
-
Baclofen